The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
    • Content Hubs
Subscribe
Subscribe
The Medicine Maker / Issues / 2025 / Sept / Preparing for CPHI 2025 in Frankfurt
Industry News Sponsored

Preparing for CPHI 2025 in Frankfurt

Our interview with Tara Dougal offers a snapshot of what to expect at the event.

09/23/2025 0 min read

Sponsored By

Informa Markets

Share

Running from October 28 to 30 at Messe Frankfurt, Germany, CPHI Frankfurt is expected to draw more than 63,000 attendees. The event brings together professionals from across the drug development and manufacturing ecosystem, and will feature six content theaters, more than 2,000 exhibitors, and a packed program focusing on networking and innovation. New zones have also been introduced to spotlight topics such as digital health technologies, AI-powered drug development, and sustainable pharma manufacturing.

Learn more about the event in this interview with Tara Dougal, Event Director – Pharma at Informa Markets.

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Recommended

Related Content

BMS Details Patient Death in Zola-Cel Multiple Sclerosis Trial
Industry News Research News Development & Clinical
BMS Details Patient Death in Zola-Cel Multiple Sclerosis Trial

November 3, 2026

2 min read

The company also reported early efficacy and safety data from the Phase I Breakfree-2 study

Off-the-Shelf CAR T Shows Early Signal in Progressive Multiple Sclerosis
Industry News Research News Development & Clinical
Off-the-Shelf CAR T Shows Early Signal in Progressive Multiple Sclerosis

November 2, 2026

2 min read

Phase I data show B-cell depletion and mostly stable or improved disability scores, but the uncontrolled study remains small and follow-up is limited

Amgen Expands Veeva Partnership
Biopharma Industry News Business & Trends
Amgen Expands Veeva Partnership

October 27, 2026

2 min read

Global deployment of Veeva Vault CRM aims to help Amgen uncover treatment barriers and accelerate the delivery of new therapies

Can Clinical Trials Collect Less Data Without Compromising Safety?
Industry News Development & Clinical Regulation & Standards
Can Clinical Trials Collect Less Data Without Compromising Safety?

October 22, 2026

5 min read

Rob DiCicco discusses how FDA–industry collaboration is helping sponsors rethink safety reporting, selective safety data collection, and pragmatic clinical trial design.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions: